UBS Group’s HeartSciences Inc Warrant HSCSW Stock Holding History

UBS Group’s Portfolio HSCSW Stock Details HSCSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71	Buy	1,086 +586	+117%	+$55	﹤0.01%	10164
2025 Q4	$23	Hold	500	–	–	﹤0.01%	10346
2025 Q3	$70	Buy	+500	New	+$54	﹤0.01%	9978
2025 Q1	–	Sell	-1,500	Closed	-$45	–	10442
2024 Q4	$45	Buy	+1,500	New	+$56	﹤0.01%	9717
2024 Q3	–	Sell	-3,439	Closed	-$117	–	9733
2024 Q2	$117	Buy	+3,439	New	+$130	﹤0.01%	9140
2023 Q4	–	Sell	-1,411	Closed	-$63	–	9556
2023 Q3	$63	Buy	1,411 +1,321	+1,468%	+$145	﹤0.01%	8973
2023 Q2	$14	Sell	90 -2,503	-97%	-$448	﹤0.01%	8715
2023 Q1	$568	Buy	2,593 +2,292	+761%	+$550	﹤0.01%	8971
2022 Q4	$87	Buy	+301	New	+$100	﹤0.01%	10418
2022 Q3	–	Sell	-1	Closed	–	–	10587
2022 Q2	$0	Buy	+1	New	–	﹤0.01%	10579

Other funds holding HSCSW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's HSCSW Position: Q1 2026 in Review

UBS Group increased its HeartSciences Inc Warrant (HSCSW) stake by 117% in Q1 2026, buying an estimated $55 and bringing the position to 1,086 shares worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #10164.

UBS Group first reported a position in HSCSW in Q2 2022 and has held it in 10 quarters since. The position peaked at $568 in Q1 2023. 3 funds tracked by Wall St. Rank hold HSCSW as of Q1 2026.

UBS Group held 1,086 shares of HeartSciences Inc Warrant worth $71 as of Q1 2026.
UBS Group bought 586 HeartSciences Inc Warrant shares in Q1 2026, an estimated $55.
HeartSciences Inc Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10164 holding.
UBS Group first reported a position in HeartSciences Inc Warrant in Q2 2022 and has held it in 10 quarters since.
UBS Group's HeartSciences Inc Warrant position peaked at $568 in Q1 2023.
3 funds tracked by Wall St. Rank held HeartSciences Inc Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.